±èÂù
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ´ëÀå¾Ï, ºñ´¢±â¾Ï(½ÅÀå¾Ï, ¹æ±¤¾Ï)
Á÷
ˤ
: ºÎ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
32
ÇØ¿Ü
Predictive Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. Clinical Colorectal Cancer 2018 (In Press) (IF 4.507)
31
ÇØ¿Ü
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 2018;18:332 (IF 3.288)
30
ÇØ¿Ü
PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget 2017 (IF 5.168)
29
ÇØ¿Ü
Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis. Oncology Report 2017, 38:3011-3018 (IF 2.662)
28
ÇØ¿Ü
Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. BMC Cancer 2017, 17:615 (IF 3.288)
27
ÇØ¿Ü
Emerging Targeted Therapies in Advanced Bladder Cancer. Transl Cancer Res 2017 (IF 1.757)
26
ÇØ¿Ü
Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget 2017 (IF 5.168)
25
ÇØ¿Ü
Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-Institutional Experience with a Rare Sarcoma. APMIS 2017 (IF 1.933)
24
ÇØ¿Ü
Normalization of Tumor Vasculature by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell 2016 (IF 24.755)
23
ÇØ¿Ü
Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. BMC Cancer 2016 (IF 3.265)
1
2
3
4
5
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729